1. World Health Organization (WHO). Pneumonia of unknown cause—China. 2020. Website. who int/csr/don/05-january2020-pneumonia-of-unkown-cause-china/en/. Accessed April. 1, 2020.
2. Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. Int J Infect Dis. 2020; 92: 214-217. doi: 10.1016/j.ijid.2020.01.050
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506. doi: 10.1016/S0140- 6736(20)30183-5
4. Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, et al. A comparative study on the clinical features of coronavirus 2019 (COVID-19) pneumonia with other pneumonias. Clin Infect Dis. 2020; 71(15): 756-761. doi: 10.1093/cid/ciaa247
5. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020; 91(1): 157-160. doi: 10.23750/abm.v91i1.9397
6. Zanke AA, Thenge RR, Adhao VS. COVID-19: A pandemic declare by world health organization. IP International Journal of Comprehensive and Advanced Pharmacology. 2020; 5(2): 49-57. doi: 10.18231/j.ijcaap.2020.012
7. McIntosh K, Hirsch MS, Bloom A. Coronavirus disease 2019 (COVID-19). UpToDate Hirsch MS Bloom. 2020; 5(1).
8. Mudenda S. Letter to editor: Coronavirus disease (COVID-19): A global health problem. International Journal of Pharmaceutics & Pharmacology. 2020; 4(1): 1-2. doi: 10.31531/2581-3080.1000141
9. Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: As systematic review and meta-analysis. J Prev Med Hyg. 2020; 61(3): E304-E312. doi: 10.15167/2421-4248/jpmh2020.61.3.1530
10. Larsen JR, Martin MR, Martin JD, Kuhn P, Hicks JB. Modeling the onset of symptoms of COVID-19. Front Public Health. 2020; 8: 473. doi: 10.3389/fpubh.2020.00473
11. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; 109: 102433. doi: 10.1016/j.jaut.2020.102433
12. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061-1069. doi: 10.1001/jama.2020.1585
13. Pullen MF, Skipper CP, Hullsiek KH, Bangdiwala AS, Pastick KA, Okafor EC, et al. Symptoms of COVID-19 outpatients in the United States. Open Forum Infect Dis. 2020; 7(7): ofaa271. doi: 10.1093/ofid/ofaa271
14. Yang SN, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res. 2020; 177: 104760. doi: 10.1016/j.antiviral.2020.104760
15. Jans DA, Martin AJ, Wagstaff KM. Inhibitors of nuclear transport. Curr Opin Cell Biol. 2019; 58: 50-60. doi: 10.1016/j. ceb.2019.01.001
16. Pott-Junior H, Paoliello MMB, Miguel AdQC, da Cunha AF, de Melo Freire CC, Neves FF, et al. Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicol Rep. 2021; 8: 505-510. doi: 10.1016/j.toxrep.2021.03.003
17. Jans DA, Wagstaff KM. Ivermectin as a broad-spectrum host-directed antiviral: The real deal? Cells. 2020; 9(9): 2100. doi: 10.3390/cells9092100
18. Espitia-Hernandez G, Munguia L, Diaz-Chiguer D, LopezElizalde R, Jimenez-Ponce F. Effects of ivermectin-azithromycincholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study. Biomedical Research. 2020; 31(5): 129-133.
19. Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020; 50(SI-1): 611-619. doi: 10.3906/sag-2004-145
20. Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, Singh BR, et al. Ivermectin, a new candidate therapeutic against SARSCoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020; 19(1): 23. doi: 10.1186/s12941-020-00368-w
21. Formiga FR, Leblanc R, de Souza Rebouças J, Farias LP, de Oliveira RN, Pena L. Ivermectin: An award-winning drug with expected antiviral activity against COVID-19. J Control Release. 2021; 329: 758-761. doi: 10.1016/j.jconrel.2020.10.009
22. Panel C-TG. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. 2020.
23. Heidary F, Gharebaghi R. Ivermectin: A systematic review from antiviral effects to COVID-19 complementary regimen. The Journal of Antibiotics. 2020; 73(9): 1-10. doi: 10.1038/s41429-020-0336-z
24. Kaur H, Shekhar N, Sharma S, Sarma P, Prakash A, Medhi B. Ivermectin as a potential drug for treatment of COVID-19: An in-sync review with clinical and computational attributes. Pharmacol Rep. 2021; 73(3): 736-749. doi: 10.1007/s43440-020-00195-y
25. Lv C, Liu W, Wang B, Dang R, Qiu L, Ren J, et al. Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo. Antiviral Res. 2018; 159: 55-62. doi: 10.1016/j.antiviral.2018.09.010
26. Krolewiecki A, Lifschitz A, Moragas M, Travacio M, Valentini R, Alonso DF, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial. EClinicalMedicine. 2021; 37: 100959. doi: 10.1016/j.eclinm.2021.100959
27. Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter J-J. Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The ivermectin in COVID nineteen study. Chest Journal. 2021; 159(1): 85-92. doi: 10.1016/j.chest.2020.10.009
28. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARSCoV-2 in vitro. Antiviral Res. 2020; 178: 104787. doi: 10.1016/j.antiviral.2020.104787
29. López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: A randomized clinical trial. JAMA. 2021; 325(14): 1426-1435. doi: 10.1001/ jama.2021.3071
30. Momekov G, Momekova D. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: Antiviral levels are not likely attainable with known dosing regimens. Biotechnology & Biotechnological Equipment. 2020; 34(1): 469-474. doi: 10.1080/13102818.2020.1775118
31. Kinobe RT, Owens L. A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin’s possible mode of action against SARS-CoV-2. Fundam Clin Pharmacol. 2021; 35(2): 260-276. doi: 10.1111/fcp.12644
32. Schmith VD, Zhou J, Lohmer LR. The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19. Clin Pharmacol Ther. 2020; 108(4): 762-765. doi: 10.1002/cpt.1889
33. Croci R, Bottaro E, Chan KWK, Watanabe S, Pezzullo M, Mastrangelo E, et al. Liposomal systems as nanocarriers for the antiviral agent ivermectin. Int J Biomater. 2016; 2016: 8043983. doi: 10.1155/2016/8043983
34. Bittencourt SC, Caponi S, Maluf S. Pharmacology in the twentieth century: The science of drugs through the analysis of Goodman and Gilman’s textbook. Hist Cienc Saude Manguinhos. 2013;20(2):499-520. doi: 10.1590/S0104-59702013005000007
35. Camprubí D, Almuedo-Riera A, Martí-Soler H, Soriano A, Hurtado JC, Subirà C, et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS One. 2020; 15(11): e0242184. doi: 10.1371/journal.pone.0242184
36. World Health Organization (WHO). Therapeutics and COVID-19: Living guideline. 2021. Website. https://www.who.int/ publications/i/item/WHO-2019-nCoV-therapeutics-2021.3. Accessed April 1, 2020.
37. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021; 103: 214-216. doi: 10.1016/j.ijid.2020.11.191
38. Kim MS, An MH, Kim WJ, Hwang T-H. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. PLoS Med. 2020; 17(12): e1003501. doi: 10.1371/journal.pmed.1003501
39. Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, doubleblind, placebo-controlled trial. BMC Infect Dis. 2021; 21(1): 635. doi: 10.1186/s12879-021-06348-5
40. Abd-Elsalam S, Noor RA, Badawi R, Khalaf M, Esmail ES, Soliman S, et al. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. J Med Virol. 2021; 93(10): 5833-5838. doi: 10.1002/jmv.27122